Canaccord Genuity Reaffirms Their Hold Rating on Laboratory Corp (LH)

In a report released today, Mark Massaro from Canaccord Genuity maintained a Hold rating on Laboratory Corp (LH), with a price target of $155. The company’s shares opened today at $153.

Massaro noted:

“We lower our estimates and PT from $162 to $155, which now uses a 13.8x multiple on our lower ’19 Adj. EPS of $11.30.”

According to, Massaro is a 5-star analyst with an average return of 15.5% and a 56.5% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Quanterix Corporation.

Currently, the analyst consensus on Laboratory Corp is a Moderate Buy with an average price target of $181, implying a 18.3% upside from current levels. In a report released today, Deutsche Bank also maintained a Hold rating on the stock with a $155 price target.


See today’s analyst top recommended stocks >>

Based on Laboratory Corp’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $319 million. In comparison, last year the company had a net profit of $181 million.

Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Kerrii Anderson, a Director at LH sold 3,700 shares for a total of $604,136.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts